Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastases, Neoplasm: full-pipeline trial registry
1 of 4 indexed Metastases, Neoplasm trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Metastases, Neoplasm: 4 US clinical trials tracked, 1 recruiting.
Metastases, Neoplasm is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Pharmacyclics, running 1 of these trials.
Enrollment posture brief
Registry condition metastases-neoplasm
OPEN 1 | RECR 25% | LATE 2 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Metastases, Neoplasm lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastases, Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastases, Neoplasm is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas
Rutgers, The State University of New Jersey
NCT05419518
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
Pharmacyclics
NCT00054795
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
AstraZeneca
NCT00055471
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Eli Lilly and Company
NCT00035035
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastases, Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastases, Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastases, Neoplasm page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Metastases, Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pharmacyclics sponsors the most Metastases, Neoplasm trials on record, review their full trial history before evaluating a specific study. See Pharmacyclics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastases, Neoplasm condition card totals 4 registered trials; most-linked intervention GEMZAR; top US site state Louisiana. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.